The filing is a routine intent-to-sell notice for a small number of shares, likely for tax withholding on equity vesting. No material impact on stock price expected. Monitor future Form 4 filings to confirm actual sale and any change in insider selling patterns.
RCKT drugs
RCKT drug pipeline →Price Chart
How similar events traded
Executive Summary
Gaurav Shah, an officer and director of Rocket Pharmaceuticals, filed a Form 144 notice of intent to sell 3,020 shares of common stock, with an approximate market value of $6,796 as of the filing date. The shares were acquired through restricted stock vesting on November 11, 2026, and the sale appears to be a routine, small disposition likely to cover tax obligations from equity vesting. Given the trivial size relative to the company's $272M market cap and the insider's prior pattern of small sales, this filing is neutral and not material.
Key Facts
- Insider Gaurav Shah (Officer and Director) filed Form 144 to sell 3,020 shares of common stock.
- Estimated value of the proposed sale is approximately $6,796 based on the filing date.
- Shares were acquired via restricted stock vesting on November 11, 2026.
- The filing notes a prior sale on August 18, 2026, of 2,293 shares for $7,754, described as covering a tax obligation from vested equity award distribution.
- Company market cap is $272M; the proposed sale represents about 0.0025% of market cap.
- Recent insider activity (30 days) shows 2 sells totaling $139K, consistent with small routine dispositions.
Financial Impact
Proposed sale of 3,020 shares valued at ~$6,796, negligible relative to $272M market cap.
Risk Factors
- Form 144 is only an intent to sell; the sale may not occur.
- If the insider increases selling volume significantly in future filings, it could signal reduced confidence.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001959173-26-008010 |
| Document: 0001959173-26-008010-index.html | 0001959173-26-008010 |
| Document: 0001959173-26-008010.txt | 0001959173-26-008010 |
Track record
21 reports on RCKT
5 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +42.18% at T+20 after the Jun 12, 2026 report. 6 of 6 went positive at some point.
Filters
- Nov 13, 20263d ago 144 Neutral 2/10 Viewing Entry $2.45 Now $2.16 −11.84% settles Dec 15
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $2.30 Now $2.16 −6.09% settles Dec 14
- Nov 12, 20264d ago Insider Cluster Neutral 3/10 Entry $2.30 Now $2.16 −6.09% settles Dec 14
- Nov 12, 20264d ago 8-K Neutral 5/10 Entry $2.30 Now $2.16 −6.09% settles Dec 14
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $2.53 Now $2.16 −14.62% settles Dec 8
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $2.53 Now $2.16 −14.62% settles Dec 8
- Nov 5, 202611d ago 144 Neutral 2/10 Entry $2.44 Now $2.16 −11.29% settles Dec 4
- Oct 30, 202617d ago SC 13G/A Neutral 2/10 Entry $2.44 Now $2.16 −11.48% settles Nov 30
- Oct 6, 20265w ago 8-K Bullish 7/10 Entry $2.54 to $2.57 Now $2.16 −14.79% ▲ +1.38% +2.62% vs SPY
- Sep 15, 20268w ago 8-K Bullish 7/10 Entry $3.41 to $2.30 Now $2.16 −36.66% ▼ −32.55% −35.27% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers